The effect of non-insulin-dependent diabetes on serum concentrations of tumor-associated carbohydrate antigens of CA19-9, CA-50, and sialyl SSEA-1 in association with the Lewis blood phenotype

Decreased serum CA19‐9 is associated with improvement of insulin resistance and metabolic control in patients with obesity and type 2 diabetes after Roux‐en‐Y gastric bypass

“…Additionally, CA 19‐9 is not expressed in genotype negative subjects with Lewis blood group. It has been reported that those with the Lewis blood group phenotype of Lea (23%) had higher serum levels of CA19‐9 than those of Leb (67%) and Le(‐) (10%); but Lewis blood was not tested in the present study.…”

Evaluation of five glycoprotein tumour markers (CEA, CA-50, CA-19-9, CA-125, CA-15-3) for the prognosis of renal-cell carcinoma

“…Although there is a marked difference in expression of elevated serum levels, the relationship of CA-50 and CA-19-9 is evident from the falling mean serum levels in relation to increasing clinical stage (Table I) and to histopathological grade (Table II). One possible explanation for this relationship could be lowered serum glucose levels at higher tumour grade or stage, as found in non-insulin-dependent diabetic patients (Shimojo et al, 1990). However, we did not quantify the serum glucose of our patients.…”

“…Serum glycoprotein markers were analyzed in 154 patients with histologically verified renal-cell carcinoma who were admitted to the Department of Urology, University Hospital, Umeå, Sweden, between 1982 and1990. There were 90 males and 64 females, with a median age of 65 years (range, 25-86 years).…”

Elevated levels of CA 19-9 and CEA in pancreatic cancer-associated diabetes

“…Paradoxically, no correlation between CA 19-9 and biochemical markers of metabolic compensation in diabetes was reported by Banfi et al (1996). The mechanism for an elevation of serum CA 19-9 in patients with diabetes mellitus may be the increase in sialic acid levels and the accelerated sialylation of carbohydrate chains (Shimojo et al 1990). However, in pancreatic cancer, the elevation of CA 19-9 is due to the increased production and secretion of this antigen from malignant cells (Fry et al 2008).…”